Literature DB >> 2821601

Elevated serum levels of soluble interleukin-2 receptors in active pulmonary sarcoidosis: relative specificity and association with hypercalcemia.

E C Lawrence1, M B Berger, K P Brousseau, T M Rodriguez, S J Siegel, C C Kurman, D L Nelson.   

Abstract

We have previously reported serum elevations of the soluble form of the interleukin-2 receptor (IL-2R), a marker of T-cell activation, in sarcoidosis. In the present study, an enzyme-linked immunosorbent assay for soluble IL-2R was employed to compare sera from normal controls with those from patients with active sarcoidosis or idiopathic pulmonary fibrosis (IPF). Sera from patients with active sarcoidosis and parenchymal lung disease (radiographic Stages II or III) had geometric mean values for soluble IL-2R of 1975 units/ml compared to 640 units/ml for normal controls (p less than 0.001, Student's t-test). By contrast, soluble IL-2R levels were lower (989 units/ml, p less than 0.05 compared to normals) in patients with active sarcoidosis but no radiographic evidence for parenchymal disease (Stages 0 or I). Soluble IL-2R levels were not elevated in patients with inactive sarcoidosis. Three of the 4 sarcoidosis patients with the highest levels of soluble IL-2R also manifested hypercalcemia. While levels of soluble IL-2R were elevated for the group of patients with IPF (1171 units/ml, p less than 0.05 compared to normals), the striking elevations of soluble IL-2R noted in active sarcoidosis were not seen and there was greater overlap with normal values. We conclude that marked serum elevations of soluble IL-2R are more suggestive of active pulmonary sarcoidosis than IPF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821601

Source DB:  PubMed          Journal:  Sarcoidosis        ISSN: 0393-1447


  8 in total

1.  Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.

Authors:  J E Crabtree; L D Juby; R V Heatley; A J Lobo; D W Bullimore; A T Axon
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

2.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

3.  Sarcoidosis around the world.

Authors:  D G James
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

4.  Serum soluble interleukin-2 receptor level is a predictive marker for EBUS-TBNA-based diagnosis of sarcoidosis.

Authors:  Jun Miyata; Takunori Ogawa; Yoichi Tagami; Takashi Sato; Mikie Nagayama; Toshiyuki Hirano; Naofumi Kameyama; Koichi Fukunaga; Akihiko Kawana; Takashi Inoue
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-15       Impact factor: 0.670

5.  Spontaneous expression of the interleukin 2 receptor gene and presence of functional interleukin 2 receptors on T lymphocytes in the blood of individuals with active pulmonary sarcoidosis.

Authors:  K Konishi; D R Moller; C Saltini; M Kirby; R G Crystal
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.

Authors:  A M Berghella; P Pellegrini; D Piancatelli; D Maccarone; T Del Beato; D Giubilei; A Pomidori; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

7.  Serum levels of soluble interleukin-2 receptor in pulmonary tuberculosis.

Authors:  S J Choi; Y S Moon; B C Lee; D S Kim
Journal:  Korean J Intern Med       Date:  1990-01       Impact factor: 2.884

Review 8.  Sarcoidosis and calcium homeostasis disturbances-Do we know where we stand?

Authors:  Łukasz Gwadera; Adam Jerzy Białas; Mikołaj Aleksander Iwański; Paweł Górski; Wojciech Jerzy Piotrowski
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.